Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

budesonide/glycopyrrolate/formoterol

budesonide/glycopyrrolate/formoterol
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Breztri AEROSOL, INHALATION 160 mcg/9 mcg/4.8 mcg    
Comments:

Due to national shortage of the nebulization solutions, the formulary status of inhaler products has been temporarily adjusted to formulary, restricted to use during the albuterol/Duoneb shortage. Upon shortage resolution, these products will automatically return to their original formulary status. See Albuterol/Duoneb Shortage Mitigation for more information. (Updated Feb 2023)

Breztri is classified as non-formulary.

Interchange Breztri (160 mcg-9 mcg-4.8 mcg) twice daily to DUONEB (3 mg-0.5 mg/3 mL) four times daily and budesonide nebulization (0.5 mg/2 mL) twice daily.

ORDERED FORMULATION

THERAPEUTIC INTERCHANGE

Breztri

  • 160 mcg-9 mcg-4.8 mcg BID

Duoneb 

  • 3 mg-0.5 mg/3 mL QID

AND

budesonide nebulization

  • 0.5 mg/2 mL BID

Reviewed: December 2021 (Breztri)

Last updated: Mar. 3, 2023






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2024 Rpharmy, LLC ­ All Rights Reserved